Screening and Secondary Prevention Rheumatic Heart Disease Study
Launched by NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES, PAKISTAN · Aug 6, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Screening and Secondary Prevention Rheumatic Heart Disease Study is researching how to better identify and manage Rheumatic Heart Disease (RHD) in rural communities in Sindh. The trial involves a simple screening process, including a medical history review and a physical exam, followed by an ultrasound test to check the heart valves for any problems. If a participant is found to have RHD, they will receive appropriate treatment and may be referred to specialists, depending on how advanced the disease is. The study aims to improve the delivery of preventive antibiotics through community health workers, ensuring patients have access to necessary medications.
To be eligible for this study, participants should be from rural areas in Sindh and aged between 10 to 65 years. Those who choose not to participate will be excluded. Participants can expect to have follow-up imaging tests at 2 years and 5 years to monitor the progression of their heart condition. This study is currently recruiting participants, and the findings could lead to better care and outcomes for those with Rheumatic Heart Disease in these communities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Rural communities in Sindh
- Exclusion Criteria:
- • Refused to participate in the study
About National Institute Of Cardiovascular Diseases, Pakistan
The National Institute of Cardiovascular Diseases (NICVD) in Pakistan is a leading healthcare institution dedicated to the prevention, diagnosis, and treatment of cardiovascular diseases. As a prominent clinical trial sponsor, NICVD is committed to advancing cardiovascular research through rigorous scientific inquiry and innovative therapeutic interventions. The institute collaborates with national and international partners to conduct clinical trials that aim to improve patient outcomes and enhance the understanding of cardiovascular health. With a focus on evidence-based practices, NICVD plays a pivotal role in shaping cardiovascular care in Pakistan and contributing to global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Sabha Bhatti, MD
Principal Investigator
National Institute of Cardiovascular Diseases
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported